1Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018;68:394–424.
2Jiang J, Li J, Yunxia Z, Zhu H, Liu J, Pumill C: The role of prostatitis in prostate cancer: Meta-analysis. PloS one 2013;8:e85179.
3Platz EA, De Marzo AM: Epidemiology of inflammation and prostate cancer. The Journal of urology 2004;171:S36–40.
4Dennis LK, Lynch CF, Torner JC: Epidemiologic association between prostatitis and prostate cancer. Urology 2002;60:78–83.
5Sartor RB: Mechanisms of disease: Pathogenesis of crohn’s disease and ulcerative colitis. Nature clinical practice Gastroenterology & hepatology 2006;3:390–407.
6Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T: Risk of extra-intestinal cancer in inflammatory bowel disease: Meta-analysis of population-based cohort studies. The American journal of gastroenterology 2010;105:1480–1487.
7Loo SY, Vutcovici M, Bitton A, Lakatos PL, Azoulay L, Suissa S, Brassard P: Risk of malignant cancers in inflammatory bowel disease. Journal of Crohn’s & colitis 2019
8Mosher CA, Brown GR, Weideman RA, Crook TW, Cipher DJ, Spechler SJ, Feagins LA: Incidence of colorectal cancer and extracolonic cancers in veteran patients with inflammatory bowel disease. Inflammatory bowel diseases 2018;24:617–623.
9Burns JA, Weiner AB, Catalona WJ, Li EV, Schaeffer EM, Hanauer SB, Strong S, Burns J, Hussain MHA, Kundu SD: Inflammatory bowel disease and the risk of prostate cancer. European urology 2018
10So J, Tang W, Leung WK, Li M, Lo FH, Wong MTL, Sze ASF, Leung CM, Tsang SWC, Shan EHS, Chan KH, Lam BCY, Hui AJ, Chow WH, Lam TY, Lam V, Lee TW, Lo HHH, Tang CM, Wong CL, Wu JCY, Chan FKL, Sung JJY, Harbord M, Ng SC: Cancer risk in 2621 chinese patients with inflammatory bowel disease: A population-based cohort study. Inflammatory bowel diseases 2017;23:2061–2068.
11Jung YS, Han M, Park S, Kim WH, Cheon JH: Cancer risk in the early stages of inflammatory bowel disease in korean patients: A nationwide population-based study. Journal of Crohn’s & colitis 2017;11:954–962.
12Hovde Ø, Hoivik ML, Henriksen M, Solberg IC, Smastuen MC, Moum BA: Malignancies in patients with inflammatory bowel disease: Results from 20 years of follow-up in the ibsen study. Journal of Crohn’s & colitis 2017;11:571–577.
13Wilson JC, Furlano RI, Jick SS, Meier CR: A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease. Journal of gastroenterology 2016;51:1050–1062.
14Kappelman MD, Farkas DK, Long MD, Erichsen R, Sandler RS, Sorensen HT, Baron JA: Risk of cancer in patients with inflammatory bowel diseases: A nationwide population-based cohort study with 30 years of follow-up evaluation. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2014;12:265–273.e261.
15Jussila A, Virta LJ, Pukkala E, Farkkila MA: Malignancies in patients with inflammatory bowel disease: A nationwide register study in finland. Scandinavian journal of gastroenterology 2013;48:1405–1413.
16Jess T, Horvath-Puho E, Fallingborg J, Rasmussen HH, Jacobsen BA: Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: A danish population-based cohort study. The American journal of gastroenterology 2013;108:1869–1876.
17Hemminki K, Li X, Sundquist J, Sundquist K: Cancer risks in crohn disease patients. Annals of oncology: official journal of the European Society for Medical Oncology 2009;20:574–580.
18Hemminki K, Li X, Sundquist J, Sundquist K: Cancer risks in ulcerative colitis patients. International journal of cancer 2008;123:1417–1421.
19Bernstein CN, Blanchard JF, Kliewer E, Wajda A: Cancer risk in patients with inflammatory bowel disease: A population-based study. Cancer 2001;91:854–862.
20Karlen P, Lofberg R, Brostrom O, Leijonmarck CE, Hellers G, Persson PG: Increased risk of cancer in ulcerative colitis: A population-based cohort study. The American journal of gastroenterology 1999;94:1047–1052.
21Ekbom A, Helmick C, Zack M, Adami HO: Extracolonic malignancies in inflammatory bowel disease. Cancer 1991;67:2015–2019.
22Moher D, Liberati A, Tetzlaff J, Altman DG, Group P: Preferred reporting items for systematic reviews and meta-analyses: The prisma statement. International journal of surgery 2010;8:336–341.
23Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of observational studies in epidemiology (moose) group. Jama 2000;283:2008–2012.
24Stang A: Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology 2010;25:603–605.
25Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–1101.
26Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. Bmj 1997;315:629–634.
27Yadav S, Singh S, Harmsen WS, Edakkanambeth Varayil J, Tremaine WJ, Loftus EV, Jr.: Effect of medications on risk of cancer in patients with inflammatory bowel diseases: A population-based cohort study from olmsted county, minnesota. Mayo Clinic proceedings 2015;90:738–746.
28Biancone L, Onali S, Petruzziello C, Calabrese E, Pallone F: Cancer and immunomodulators in inflammatory bowel diseases. Inflammatory bowel diseases 2015;21:674–698.
29Nakai Y, Nonomura N: Inflammation and prostate carcinogenesis. International journal of urology: official journal of the Japanese Urological Association 2013;20:150–160.
30Axelrad JE, Lichtiger S, Yajnik V: Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. World journal of gastroenterology 2016;22:4794–4801.
31Subramaniam K, D’Rozario J, Pavli P: Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: A review. Journal of gastroenterology and hepatology 2013;28:24–30.
32Kappelman MD, Porter CQ, Galanko JA, Rifas-Shiman SL, Ollendorf DA, Sandler RS, Finkelstein JA: Utilization of healthcare resources by u.S. Children and adults with inflammatory bowel disease. Inflammatory bowel diseases 2011;17:62–68.
33Rais R, Jiang W, Zhai H, Wozniak KM, Stathis M, Hollinger KR, Thomas AG, Rojas C, Vornov JJ, Marohn M, Li X, Slusher BS: Folh1/gcpii is elevated in ibd patients, and its inhibition ameliorates murine ibd abnormalities. JCI insight 2016;1
34Ghosh A, Heston WD: Tumor target prostate specific membrane antigen (psma) and its regulation in prostate cancer. Journal of cellular biochemistry 2004;91:528–539.